Anika Therapeutics Inc (ANIK) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Anika Therapeutics Inc stock (ANIK) is currently trading at $14.56. Anika Therapeutics Inc PS ratio (Price-to-Sales) is 1.77. Analyst consensus price target for ANIK is $17.50. WallStSmart rates ANIK as Sell.
- ANIK PE ratio analysis and historical PE chart
- ANIK PS ratio (Price-to-Sales) history and trend
- ANIK intrinsic value — DCF, Graham Number, EPV models
- ANIK stock price prediction 2025 2026 2027 2028 2029 2030
- ANIK fair value vs current price
- ANIK insider transactions and insider buying
- Is ANIK undervalued or overvalued?
- Anika Therapeutics Inc financial analysis — revenue, earnings, cash flow
- ANIK Piotroski F-Score and Altman Z-Score
- ANIK analyst price target and Smart Rating
Anika Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Anika Therapeutics Inc (ANIK) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, institutional own.. Concerns around market cap and peg ratio. Significant fundamental concerns warrant caution or avoidance.
Anika Therapeutics Inc (ANIK) Key Strengths (3)
92.98% of shares held by major funds and institutions
Paying $1.77 for every $1 of annual revenue
Trading at 1.29x book value, attractively priced
Supporting Valuation Data
Anika Therapeutics Inc (ANIK) Areas to Watch (6)
Company is destroying shareholder value
Earnings declining -50.50%, profits shrinking
Company is losing money with a negative profit margin
Near-zero operating margins, business under pressure
Very expensive relative to growth, significant premium
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Anika Therapeutics Inc (ANIK) Detailed Analysis Report
Overall Assessment
This company scores 33/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 3 register as strengths (avg 8.7/10) while 6 fall into concern territory (avg 1.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Price/Sales, Price/Book. Valuation metrics including Price/Sales (1.77), Price/Book (1.29) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, EPS Growth, Profit Margin. Some valuation metrics including PEG Ratio (5.54) suggest expensive pricing. Growth concerns include EPS Growth at -50.50%, which may limit upside. Profitability pressure is visible in Return on Equity at -6.71%, Operating Margin at 2.11%, Profit Margin at -9.64%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -6.71% needing improvement to support the investment thesis. Third, growth sustainability, with EPS Growth at -50.50% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and EPS Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ANIK Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ANIK's Price-to-Sales ratio of 1.77x trades at a deep discount to its historical average of 4.82x (6th percentile). The current valuation is 84% below its historical high of 11.18x set in Sep 2007, and 28% above its historical low of 1.38x in Feb 2009.
Compare ANIK with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Anika Therapeutics Inc (ANIK) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Anika Therapeutics Inc is in a turnaround phase, with management focused on restoring profitability. The company is currently unprofitable, posting a -9.6% profit margin.
Key Findings
Generating 4M in free cash flow and 5M in operating cash flow. Earnings are translating into actual cash generation.
Debt-to-equity ratio of 0.17 indicates a conservative balance sheet with 58M in cash.
The company is unprofitable with a -9.6% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Anika Therapeutics Inc.
Bottom Line
Anika Therapeutics Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Anika Therapeutics Inc(ANIK)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Anika Therapeutics, Inc., is a joint preservation company in the United States, Europe, and internationally. The company is headquartered in Bedford, Massachusetts.